Literature DB >> 3499713

Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.

N E Byars1, A C Allison.   

Abstract

Adjuvant formulations which elicit both humoral and cell-mediated immunity will be required for vaccines based on peptides, viral and bacterial subunits and genetically engineered antigens. This report describes an adjuvant formulation which increases both cell-mediated and humoral immunity and is free of significant side effects encountered with other adjuvants or vehicles. The components include the threonyl analogue of muramyl dipeptide, Tween 80, Pluronic L121 and squalane. This formulation was found to be effective with several antigens, in several species, including rodents, cats and monkeys. These results suggest that the formulation will be useful for both human and veterinary vaccines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499713     DOI: 10.1016/0264-410x(87)90105-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Analysis of cDNAs coding for immunologically dominant antigens from an oncosphere-specific cDNA library of Echinococcus multilocularis.

Authors:  Armin Merckelbach; Martina Wager; Richard Lucius
Journal:  Parasitol Res       Date:  2003-06-26       Impact factor: 2.289

Review 2.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

3.  Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.

Authors:  Neeta Jain-Gupta; Araceli Contreras-Rodriguez; Ramesh Vemulapalli; Sharon G Witonsky; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

4.  New age adjuvants and delivery systems for subunit vaccines.

Authors:  S Kurella; M Manocha; L Sabhnani; B Thomas; D N Rao
Journal:  Indian J Clin Biochem       Date:  2000-08

5.  Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.

Authors:  D M Lidgate; R C Fu; N E Byars; L C Foster; J S Fleitman
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

6.  Characterization of a 10- to 14-kilodalton protease-sensitive Mycobacterium tuberculosis H37Ra antigen that stimulates human gamma delta T cells.

Authors:  W H Boom; K N Balaji; R Nayak; K Tsukaguchi; K A Chervenak
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.

Authors:  M F Powell; L C Foster; A R Becker; W Lee
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Induction of murine T-helper-cell responses to the filarial nematode Brugia malayi.

Authors:  E Pearlman; F E Hazlett; W H Boom; J W Kazura
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera.

Authors:  J C Hierholzer; Y O Stone; J R Broderson
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.